市場調查報告書
商品編碼
1138313
全球細胞分離市場-2022-2029Global Cell Isolation Market - 2022-2029 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球細胞分離市場的增長受到某些因素的推動,例如人口老齡化導致慢性病患病率上升、細胞分離技術進步、對生物製藥的需求增加以及乾細胞研究的增加。這些是推動市場增長的主要因素之一。
預計慢性病的增加將在預測期內推動全球細胞分離市場。
根據世界衛生組織 (WHO) 的數據,癌症每年佔全球死亡人數的 13%。此外,預計未來幾十年癌症發病率將增加70%,全球老齡化人口更易患癌症。預計在未來幾十年內將增加近一倍。按地區劃分,亞洲的癌症發病率高於其他地區。就背景而言,2012 年亞洲受癌症影響的人口為 667 萬,預計到 2030 年將達到 1084 萬。與所有其他地區的累積受影響人口相比,亞洲的癌症發病率很高。就增長率而言,該地區的癌症發病率也在以 2.7% 的顯著複合年增長率增長。歐洲的癌症發病率第二高,其次是北美。在癌症發病率增加方面,預計歐洲在預測期內將經歷最慢的增長。在癌症發病率增長方面,中東和北非和南美被認為是前兩個地區,2012 年至 2030 年的複合年增長率分別為 3.1% 和 2.9%。因此,全球癌症發病率上升正在推動細胞分離市場的增長。
嚴格的法規、細胞分離設備的高成本以及與胚胎幹細胞研究相關的倫理問題阻礙了細胞分離市場的增長。
然而,細胞分離市場受到多種因素的阻礙,例如嚴格的監管、細胞分離儀器的高成本以及與胚胎幹細胞研究相關的倫理問題。細胞生物學研究需要使用動物和人類。這些細胞還用於可能傷害動物和人類的藥物的體內毒性和藥代動力學研究。此外,幹細胞研究將人類胚胎用於臨床應用,這往往會導致胚胎破壞。監控此類活動需要嚴格的監管,並由世界各地的監管機構強制執行。監管機構包括中央幹細胞研究倫理委員會 (ZES)、人類受精和胚胎機構 (HFEA)、人體組織機構 (HTA) 以及藥品和醫療產品監管機構 (MHRA)。因此,此類倫理問題和對研究細胞使用的限制限制了細胞生物學研究。
隨著 COVID-19 的爆發,實驗室正在加緊研發,以尋找可以及早減輕冠狀病毒症狀的解決方案。這些正在進行的臨床試驗和研究預計將增加對細胞分離產品的需求,從而推動市場增長。
行業分析
全球細胞分離市場根據波特五力分析、供應鏈分析、監管分析、定價分析和未滿足的需求等各種行業因素對市場進行了深入分析。
全球細胞分離市場報告提供大約 40 多個市場數據表、45 多個數字和 180 頁內容。
Cell Isolation Market is expected to grow at a high CAGR of 17.2% during the forecasting period (2022 - 2029).
Cell isolation (or cell separation) is a process used for sorting cells from a heterogeneous group of cells into the specific populations without contamination. This technique helps many cell-based therapies to improve the quality of the treatment. Cell isolation techniques are widely used for biomolecule isolation for the production of vaccines, drugs, antibodies, enzymes, proteins, and other biotechnology products.
The global Cell Isolation market growth driven by certain factors such as rising prevalence of chronic diseases with growing geriatric population, technological advancement in cell isolation, increasing demand for biopharmaceuticals, and increasing stem cell research. are among the key factors driving the market growth.
Rising prevalence of chronic diseases, is expected to drive the global cell isolation market during the forecast period
According to the World Health Organization (WHO), cancer accounts for 13% of deaths globally every year. Moreover, a 70% increase in cancer incidences is anticipated over the next couple of decades and the global geriatric population, as they are more prone to cancer, is anticipated to nearly double from 12% to 22%, from 2015 to 2022. By region, cancer incidence is highest in Asia compared to other regions. Contextually, the incidence population of cancers in Asia was 6.67 million in 2012 and is anticipated to reach 10.84 by 2030. The cancer incidence in Asia is higher compared to the cumulative incidence population of all other regions. In terms of growth rate too, the incidence rate of cancers is growing at a notable CAGR of 2.7% in this region. Europe has the second-highest cancer incidence, followed by North America. In terms of the increase in cancer incidence, Europe is anticipated to have the slowest growth in the forecast period. In terms of growth of cancer incidence, Middle and North Africa and South America are considered to the top two regions with CAGR of 3.1% and 2.9%, from 2012 to 2030, respectively. Hence, with the rising prevalence of cancer globally is driving the growth of the cell isolation market.
Stringent regulations, high cost of cell isolation instruments, and ethical issues related to embryonic stem cell research hampering the growth of the cell isolation market
However, the cell isolation market is hampered by several factors such as stringent regulations, high cost of cell isolation instruments, and ethical issues related to embryonic stem cell research. Cell biology research necessitates the use of animals and humans. These cells are also used for in vivo toxicity and pharmacokinetic testing of drugs, which may harm animals and humans. Also, stem cell research studies use human embryos for clinical applications that often lead to the destruction of embryos. Monitoring of such activities requires stringent regulations which are implemented by regulatory bodies globally. Some of the regulating authorities include Central Ethics Committee for Stem Cell Research (ZES), Human Fertilization and Embryology Authority (HFEA), Human Tissue Authority (HTA), Medicines and Healthcare Products Regulatory Agency (MHRA) and, among others. Hence, with the presence of such ethical concerns and restrictions on the use of cells for research is limiting cell biology research.
Due to the outbreak of COVID-19, research labs have increased their research and development to find solutions which can minimize the symptoms of coronavirus at early stages. These ongoing clinical trials and research is expected to increase the demand for cell isolation products, and hence driving the market growth.
Industry Analysis
The global cell isolation market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, pricing analysis, unmet needs.
The consumables segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The consumables segment accounted for the largest market share in 2019, due to rising investments by major companies to develop technologically advanced products as well as the repetitive use of consumables. Consumables are further classified into reagents & kits, disposables, and beads. On the other hand, the instruments segment is anticipated to grow at the fastest growth rate over the forecast period, owing to advancements in products such as flow cytometers, centrifuges, magnetic-activated cell separator systems, and filtration systems. The innovations in instruments provide efficient cell separation in diagnostics, research, and other applications.
North America region holds the largest market share of the global cell isolation market
North America region is dominating the global cell isolation market accounted for the largest market share in 2021, owing to advanced healthcare infrastructure for life science research, the large presence of major players focusing on the development of novel treatments, and rising prevalence of cancer in this region. For instance, according to the estimates of the GLOBOCAN in 2020, there were an estimated 2,281,658 new cancer cases diagnosed and 612,390 deaths due to cancer in the United States. The Canadian Cancer Society (CCS) estimated that in 2020, approximately 29,800 Canadians would be diagnosed with lung cancer. Represents 13% of all new cancer cases. About 21,200 Canadians are expected to die from lung cancer. Means 25% of all cancer deaths in 2020. In addition, increasing government support for cancer and stem cell research and the expansion of biotechnology and biopharmaceutical industries globally are contributing to the growth of the market. In April 2018, STEMCELL Technologies announced a US$ 45 million joint agreement between the governments of Canada and British Columbia to help the company build an advanced manufacturing facility.
The global cell isolation market is fragmented with major players dominating the market. Some of the major players contributing to the growth of the cell isolation market are Becton Dickinson and Company, Beckman Coulter, Inc., GE Healthcare, Merck KgaA, Miltenyi Biotec, Thermo Fisher Scientific, Bio-Rad Laboratories Inc., among others. The key players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Cell Isolation market globally. For instance,
In November 2019, MicroMedicine, Inc., a life sciences technology company, launched its patented one-of-a-kind white blood cell isolation technology, the Sorterra Cell Isolation System. This new automated technology gently and reliably isolates white blood cells from human peripheral blood using microfluidic channels without the use of centrifugation or labelling. Sorterra is intended for use in research and development and clinical research labs. Global Cell Isolation Market - Key Companies to Watch
Bio-Rad Laboratories
Overview: Bio-Rad Laboratories, Inc. is an American company that continued to produce innovative and useful products in the healthcare industry that assist life science researchers in accelerating the discovery process, and medical diagnostic labs obtain faster better results.
Product Portfolio: Bio-Plex Multiplex System- The Bio-Plex System offers high-performance readers, industry-leading software, and sensitive assays in ready-to-use or custom configurations, enabling you to obtain high-quality data from limited samples.
The global cell isolation market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.